FDA report questions efficacy of Pfizer's kidney cancer drug Inlyta - PMLiVE PDF Print
PMLiVE
Inlyta is due for review by the FDA's Oncologic Drugs Advisory Committee (ODAC) on December 7 as a second-line treatment for patients with advanced renal cell carcinoma, based on the results of a single efficacy study in 723 patients which compared

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.